[go: up one dir, main page]

GT200000155A - Tratamiento de combinacion con il - 1ra y compuestos que inhiben el procesamiento y la liberacion il - 1. - Google Patents

Tratamiento de combinacion con il - 1ra y compuestos que inhiben el procesamiento y la liberacion il - 1.

Info

Publication number
GT200000155A
GT200000155A GT200000155A GT200000155A GT200000155A GT 200000155 A GT200000155 A GT 200000155A GT 200000155 A GT200000155 A GT 200000155A GT 200000155 A GT200000155 A GT 200000155A GT 200000155 A GT200000155 A GT 200000155A
Authority
GT
Guatemala
Prior art keywords
morby
compositions
methods
release
treatment
Prior art date
Application number
GT200000155A
Other languages
English (en)
Inventor
Bruce Henry Littman
Thasia Louise Goodwin Woodworth
Mark Anthony Dombroski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200000155A publication Critical patent/GT200000155A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

EL INVENTO SE REFIERE A METODOS Y COMPOSICIONES PAR TRATAR Y PREVENIR ESTADOS MORBOSOS MEDIADOS POR LA IINTERLEUQUINA 1 ( IL 1RA ). EN LOS METODOS Y LAS COMPOSICIONES SE USA UN POLIPEPTIDO ANTAGONISTA DEL RECEPTOR DE LA INTERLEUCINA 1, O UNA VARIANTE DEL MISMO, EN COMBINACION CON UN AGENTE NO ESTEROIDE QUE INHIBE EL PROCESAMIENTO Y LA LIBERACION DE IL 1RA. AUNQUE LOS METODOS Y LAS COMPOSICIONES DEL PRESENTE INVENTO SON UTILES PARA EL TRATAMIENTO DE CUALQUIER ESTADO MORBOSO MEDIADO POR IL 1, EL ESTADO MORBOSO MEDIADO POR IL 1 ES PREFERIBLEMENTE SELECCIONADO DEL GRUPO QUE CONSISTE EN ENFERMEDADES CEREBRALES MEDIADAS POR CITOQUINAS, TALES COMO LA ENFERMEDAD DE ALZHEIMER; ENFERMEDADES INFLAMATORIAS TALES COMO INFLAMACIONES AGUDA Y CRONICA Y ARTRITIS REUMATOIDE; ENFERMEDADES DEGENERATIVAS DEL CARTILAGO Y OTRAS.
GT200000155A 1999-09-14 2000-09-14 Tratamiento de combinacion con il - 1ra y compuestos que inhiben el procesamiento y la liberacion il - 1. GT200000155A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15401099P 1999-09-14 1999-09-14

Publications (1)

Publication Number Publication Date
GT200000155A true GT200000155A (es) 2002-03-08

Family

ID=22549650

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200000155A GT200000155A (es) 1999-09-14 2000-09-14 Tratamiento de combinacion con il - 1ra y compuestos que inhiben el procesamiento y la liberacion il - 1.

Country Status (13)

Country Link
EP (1) EP1214087A1 (es)
JP (1) JP2003509378A (es)
AR (1) AR033650A1 (es)
AU (1) AU6464400A (es)
BR (1) BR0014003A (es)
CA (1) CA2383026A1 (es)
CO (1) CO5190701A1 (es)
EC (1) ECSP003652A (es)
GT (1) GT200000155A (es)
PA (1) PA8502901A1 (es)
PE (1) PE20010685A1 (es)
TN (1) TNSN00183A1 (es)
WO (1) WO2001019390A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007531738A (ja) 2004-04-02 2007-11-08 アムジエン・インコーポレーテツド ＩＬ−１ｒａの凝集を低下させる方法
WO2008129288A2 (en) * 2007-04-19 2008-10-30 Boehringer Ingelheim International Gmbh Disulfonamides useful in the treatment of inflammation
AU2016222278B2 (en) * 2015-02-16 2020-07-09 The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Sulfonylureas and related compounds and use of same
JP2019512009A (ja) 2016-02-16 2019-05-09 ザ・ユニバーシティ・オブ・クイーンズランド スルホニルウレアおよび関連化合物ならびにこれらの利用
ES2855732T3 (es) * 2016-04-18 2021-09-24 Novartis Ag Compuestos y composiciones para tratar afecciones asociadas con la actividad de NLRP
EP3571187B1 (en) 2017-01-23 2023-11-22 Genentech, Inc. Chemical compounds as inhibitors of interleukin-1 activity
BR112019024831A2 (pt) 2017-05-24 2020-06-09 The University Of Queensland composto, sal, solvato ou pró-droga, composição farmacêutica, método de tratamento ou prevenção de uma doença, método para inibir o nlrp3
EP3634951B8 (en) 2017-06-09 2024-08-21 Zydus Lifesciences Limited Novel substituted sulfoximine compounds
LT3661925T (lt) 2017-07-07 2022-03-10 Inflazome Limited Naujieji sulfonamido karboksamido junginiai
EP3649112A1 (en) 2017-07-07 2020-05-13 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
SI3658539T1 (sl) 2017-07-24 2024-06-28 Novartis Ag Spojine in sestavki za zdravljenje stanj, povezanih z delovanjem nlrp
US11926600B2 (en) 2017-08-15 2024-03-12 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
BR112020002906A2 (pt) 2017-08-15 2020-08-04 Inflazome Limited novos compostos de sulfonamida-carboxamida
CA3071150A1 (en) * 2017-08-15 2019-02-21 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
EP3668840A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Novel sulfonamide carboxamide compounds
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
WO2019043610A1 (en) 2017-08-31 2019-03-07 Cadila Healthcare Limited NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
WO2019068772A1 (en) 2017-10-03 2019-04-11 Inflazome Limited NEW COMPOUNDS
WO2019092171A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
RU2020115098A (ru) 2017-11-09 2021-12-10 Инфлазоум Лимитед Соединения новых сульфонамидкарбоксамидов
EP3759102A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
US12030879B2 (en) 2018-03-02 2024-07-09 Inflazome Limited Sulfonyl acetamides as NLRP3 inhibitors
WO2019166628A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
EP3759077A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
US12168653B2 (en) 2018-03-02 2024-12-17 Inflazome Limited Sulfonamide derivates as NLRP3 inhibitors
WO2019166632A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
GB201806578D0 (en) * 2018-04-23 2018-06-06 Inflazome Ltd Novel compound
WO2020010143A1 (en) 2018-07-03 2020-01-09 Novartis Inflammasome Research, Inc. Nlrp modulators
KR20210034596A (ko) 2018-07-20 2021-03-30 에프. 호프만-라 로슈 아게 인터류킨-1 활성의 저해제로서 술폰이미드아미드 화합물
PE20211049A1 (es) 2018-07-20 2021-06-04 Hoffmann La Roche Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1
US12187702B2 (en) 2018-08-15 2025-01-07 Inflazome Limited Sulfonamideurea compounds
JP2022505525A (ja) * 2018-10-24 2022-01-14 ノバルティス アーゲー Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物
CN120208846A (zh) 2019-01-14 2025-06-27 载度思生命科学有限公司 经取代的磺酰脲类衍生物
EP4157860A4 (en) * 2020-05-25 2024-03-06 Beijing Vdjbio Co., Ltd. An interleukin-1 receptor antagonist and a fusion protein containing the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874424A (en) * 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
EP0964849B1 (en) * 1997-01-29 2003-06-04 Pfizer Inc. Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
US6015790A (en) * 1997-10-06 2000-01-18 Basf Aktiengesellschaft Methods and compositions for treating rheumatoid arthritis
EP0987552A3 (en) * 1998-08-31 2000-06-07 Pfizer Products Inc. Diarylsulfonylurea binding proteins

Also Published As

Publication number Publication date
CO5190701A1 (es) 2002-08-29
TNSN00183A1 (fr) 2005-11-10
JP2003509378A (ja) 2003-03-11
CA2383026A1 (en) 2001-03-22
BR0014003A (pt) 2002-05-21
AU6464400A (en) 2001-04-17
PA8502901A1 (es) 2002-02-21
AR033650A1 (es) 2004-01-07
WO2001019390A1 (en) 2001-03-22
PE20010685A1 (es) 2001-07-03
EP1214087A1 (en) 2002-06-19
ECSP003652A (es) 2002-04-23

Similar Documents

Publication Publication Date Title
GT200000155A (es) Tratamiento de combinacion con il - 1ra y compuestos que inhiben el procesamiento y la liberacion il - 1.
MX389798B (es) Azolopirimidina para el tratamiento de trastornos relacionados con el cáncer.
UY38742A (es) Compuestos de 2,3,5-pyrazolo[1,5-a]pirimidina trisustituida
ECSP066972A (es) Profármacos mutuos de glucosamina y glucosamina/anti-inflamatorio, composiciones, y métodos
ECSP034809A (es) Ciclobuteno-1,2-dionas 3,4-disustituidas como ligandos del receptor de quimocina cxc
CL2007001996A1 (es) Compuestos derivados de heteroarilos nitrogenados sustituidos con fenilo, inhibidores de la produccion de citoquinas; composicion farmaceutica que los comprende; y sus usos en el tratamiento del cancer, infecciones, enfermedades inflamatorias y autoinmunes.
ECSP088752A (es) Formulaciones para administración parenteral de compuestos y sus usos
AR048912A1 (es) Inmunoglobulinas anti-nogo
CU23029A3 (es) Analogos sustituidos del benzopirano para el tratamiento de la inflamacion
RU94015838A (ru) Производные бензофуранил- или бензотиофенилалкан-карбоновой кислоты, смесь их изомеров или отдельные изомеры и их соли
MXPA04006039A (es) Metodo para el tratamiento de afecciones vasculares y neuronales perifericas.
CY1112317T1 (el) Καινοφανης κρυσταλλικη μορφη ενος παραγωγου της πυριδαζινο [4,5-β] ινδολης
AR030021A1 (es) COMPUESTO DE UNA PIRIMIDINONAS SUSTITUIDA,COMPOSICIoN FARMACÉUTICA QUE LO COMPRENDE Y EL USO DE DICHO COMPUESTO Y DE DICHA COMPOSICIoN EN LA FABRICACIoN DE MEDICAMENTOS uTILES PARA LA INHIBICION SELECTIVA DE LA CASCADA DE COAGULACIoN
KR920021145A (ko) 뇌 글루타메이트의 과다방출의 억제에 유용한 제형
UY37813A (es) Derivados de pirrolopiridina sustituidos
ES2058306T3 (es) Tetralinas substituidas, cromanos y compuestos relacionados en el tratamiento del asma, artritis y enfermedades relacionadas.
AR058561A1 (es) Control de la estabilidad de la forma de dosificacion de cci -779 a traves del control de impurezas de sustancias de farmaco
PA8457001A1 (es) Derivados del 2-(4-aril o heteroaril-piperazin-i-ilmetil)-1h-indol
DK1032556T3 (da) Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder
UY27413A1 (es) Agonistas de la oxitocina
DK0710239T3 (da) Nye 9-N-bicycliske nucleosidmidler anvendelige som selektive inhibitorer af proinflammatoriske cytokiner
AR029134A1 (es) Metodos para el tratamiento o profilaxis de efectos patogenicos mediados por la aldosterona en un sujeto usando un antagonista de aldosterona epoxi esteroidal
ECSP056006A (es) Composiciones farmacéuticas que comprenden una combinación de rapamicina o su derivado y pimecrolimus para el tratamiento de enfermedades inflamatorias e inmunológicamente mediadas
ES2057341T3 (es) Ciclohexenos substituidos como agentes para el sistema nervioso central.
MX9200948A (es) Composicion farmaceutica para el tratamiento de isquemia cerebral en mamiferos.